Here’s what you should know.
1. The companies entered into the agreement after evidence emerged suggesting the anti-PD-1 therapy’s immune activity enhances when combined with a MEK inhibitor.
2. The clinical trial aims to establish a recommended dose regimen, and to explore preliminary several novel regimens’ anti-tumor activity.
3. The companies expect the trial to begin in the second half of 2017. The first study’s results will shape future clinical developmental decisions.
4. Merck is sponsoring the trial.
More articles on gastroenterology:
European scientists developing advanced endoscope — 3 insights
GI leader to know: Dr. Jennifer Dorfmeister of Illinois Gastro
Unique enzyme could allow gluten-sensitive patients to digest gluten — 3 key notes
